Cancers 2013, 5(2), 418-429; doi:10.3390/cancers5020418
Article

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma

1 Department of Hematology/Oncology, The University of Vermont Cancer Center, 89 Beaumont Ave., Burlington, VT 05405, USA 2 Department of Medical Oncology, Fox Chase Cancer Center, Pennsylvania, PA 19111, USA 3 Department of Radiology, University of Pittsburgh Medical Center East, Pittsburgh, PA 15146, USA 4 Department of Orthopaedics, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA 5 Department of Radiation Oncology, University of New Mexico Cancer Center, Albuquerque, NM 87131, USA 6 Department of Pathology, University of New Mexico Cancer Center, Albuquerque, NM 87131, USA 7 Division of Hematology/Oncology, University of New Mexico Cancer Center, Albuquerque, NM 87131, USA
* Author to whom correspondence should be addressed.
Received: 16 February 2013; in revised form: 25 March 2013 / Accepted: 6 April 2013 / Published: 11 April 2013
(This article belongs to the Special Issue Soft Tissue and Bone Sarcoma)
PDF Full-text Download PDF Full-Text [521 KB, uploaded 11 April 2013 13:53 CEST]
Abstract: mTOR inhibitors are emerging as important anti-neoplastic agents with a wide range of clinical applications. The topoisomerase I inhibitor irinotecan is a potent DNA damaging drug, with a broad spectrum of anticancer activities. mTOR appears to enhance cancer cell survival following DNA damage, thus the inhibition of mTOR after irinotecan could theoretically show synergistic activities in patients. Both mTOR inhibitors and irinotecan have been used as single agents in soft tissue sarcomas with limited efficacy. We completed a phase I trial of the combination of the mTOR inhibitor, temsirolimus, and irinotecan in patients with advanced soft tissue sarcoma. Seventeen patients were recruited. The Phase II recommended dose is 20 mg of temsirolimus and 80 mg/m2 of irinotecan administered on weekly basis for three out of four weeks. Most frequently encountered toxicities include cytopenias, fatigue, and gastrointestinal toxicities. Two patients (one with leiomyosarcoma and one with high grade undifferentiated sarcoma) had stable disease for more than 12 months.
Keywords: sarcoma; mTOR inhibitors; irinotecan; temsirolimus; phase I

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Verschraegen, C.F.; Movva, S.; Ji, Y.; Schmit, B.; Quinn, R.H.; Liem, B.; Bocklage, T.; Shaheen, M. A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma. Cancers 2013, 5, 418-429.

AMA Style

Verschraegen CF, Movva S, Ji Y, Schmit B, Quinn RH, Liem B, Bocklage T, Shaheen M. A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma. Cancers. 2013; 5(2):418-429.

Chicago/Turabian Style

Verschraegen, Claire F.; Movva, Sujana; Ji, Yongli; Schmit, Berndt; Quinn, Robert H.; Liem, Ben; Bocklage, Therese; Shaheen, Monte. 2013. "A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma." Cancers 5, no. 2: 418-429.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert